Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 14, 2026 - 04:46

Capricor Therapeutics has released its financial results for the second quarter of 2026 and provided a broader update on its corporate activities. The company is focused on developing cell and exosome-based therapies, with its lead candidate, deramiocel, currently under active review by the U.S. Food and Drug Administration as part of a Biologics License Application.

The company highlighted that the Phase 3 HOPE-3 trial results for deramiocel were published in The Lancet. The study met its primary endpoint, showing a statistically significant improvement in upper limb function for patients, with a p-value of 0.029. This marks a key milestone for the program as it moves through the regulatory process.

As of June 30, 2026, Capricor reported cash, cash equivalents, and marketable securities totaling approximately $238 million. The company noted that this financial position is expected to support its operations and ongoing regulatory activities.

Management will hold a conference call and webcast today at 4:30 p.m. Eastern Time to discuss the financial results and the clinical and regulatory updates in more detail. The call is intended for investors and analysts seeking a deeper look at the company's recent progress and near-term outlook.

The company continues to advance its pipeline, with deramiocel representing a potential treatment option for patients with Duchenne muscular dystrophy. Additional data and updates are expected as the FDA review process continues.